Key Takeaways Tempus AI's Genomics revenues jumped 115% year over year, driven by testing growth and acquisitions. Exact Sciences' genomics advances include Oncotype DX and Oncodetect validation in colorectal cancer. EXAS offers a stronger earnings outlook and valuation appeal, while TEM leads in share performance. Per multiple sources, the integration of genomics into cancer care has transformed treatment approaches, moving away from uniform therapies to precision medicine, where clinical decisions are tai ...

Core Viewpoint - Exact Sciences (EXAS) is expected to report a year-over-year increase in earnings and revenues for the quarter ended September 2025, with a consensus outlook indicating a significant earnings surprise potential [1][3][12]. Earnings Expectations - The consensus EPS estimate for Exact Sciences is $0.10 per share, reflecting a year-over-year increase of +147.6% [3]. - Revenues are projected to be $809.93 million, which is a 14.3% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 9.76% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Exact Sciences is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +56.25% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a strong likelihood of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy) [10][12]. - Exact Sciences currently holds a Zacks Rank of 1, reinforcing the expectation of surpassing the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Exact Sciences exceeded the expected loss of $0.02 per share by reporting earnings of $0.22, resulting in a surprise of +1,200.00% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Context - Apellis Pharmaceuticals (APLS), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings of $0.83 per share, indicating a year-over-year change of +280.4% [18]. - Apellis Pharmaceuticals has an Earnings ESP of +33.59% and a Zacks Rank of 3 (Hold), suggesting a likelihood of beating the consensus EPS estimate [19][20].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Exact Sciences (EXAS) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Exact Sciences is one of 955 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individ ...

After crashing in 2022, the Ark Innovation ETF has tripled in the last three years. Fund manager Wood is confident the gains are here to stay, dismissing fears of a bubble.Among all the growth-minded investors who have seen their portfolios soar through this year’s AI craze, one familiar name has outperformed the rest.Cathie Wood’s Ark Innovation ETF (ARKK) is up 87.1% in the last year, outperforming every other ETF and mutual fund tracked by the American Association of Individual Investors as of the end of ...

Market Overview - U.S. stocks experienced significant gains in Q3 2025, with the Nasdaq Composite, S&P 500, and Dow Jones Industrial Average rising by 11.2%, 7.8%, and 5.2% respectively [1] - The growth was fueled by expectations of further Federal Reserve rate cuts, strong Q2 earnings, and optimism surrounding artificial intelligence (AI) [2] Recommended Growth Stocks - Five growth stocks are recommended for Q4 2025: Micron Technology Inc. (MU), Workday Inc. (WDAY), Exact Sciences Corp. (EXAS), Evercore Inc. (EVR), and Coeur Mining Inc. (CDE) [2] - These stocks exhibit strong revenue and earnings growth potential, with positive earnings estimate revisions in the past 30 days [3] Micron Technology Inc. (MU) - Micron is a leader in the AI infrastructure boom, driven by high demand for its high-bandwidth memory (HBM) solutions and record sales in the data center market [6][9] - The company is capitalizing on the growing adoption of AI servers, which require more memory than traditional servers, boosting demand for DRAM [7] - Micron's expected revenue and earnings growth rates are 42.4% and over 100% respectively for the current year, with a 27% improvement in the Zacks Consensus Estimate for earnings over the last 30 days [10] Workday Inc. (WDAY) - Workday's diversified product portfolio and cloud-based business model are key growth drivers, with strong customer traction in international markets [11] - Significant investment from Elliott Investment Management is expected to enhance innovation, particularly in AI and machine learning [12] - Workday's expected revenue and earnings growth rates are 12.6% and 21.1% respectively for the current year, with a 0.3% improvement in the Zacks Consensus Estimate for earnings over the last 30 days [13] Exact Sciences Corp. (EXAS) - Exact Sciences benefits from strong adoption of its Cologuard product, with the recent introduction of Cologuard Plus gaining Medicare coverage [14] - The launch of Oncodetect has advanced MRD testing, with secured Medicare reimbursement opening access for cancer patients [15] - Exact Sciences has an expected revenue and earnings growth rate of 14.4% and over 100% respectively for the current year, with a 9.1% improvement in the Zacks Consensus Estimate for earnings over the last 30 days [16] Evercore Inc. (EVR) - Evercore is expanding its advisory client base and diversifying revenue sources, which is expected to support top-line growth [17] - The company has a strong liquidity position, allowing for capital distribution through dividend hikes and share repurchase programs [17] - Evercore's expected revenue and earnings growth rates are 17.4% and 34.4% respectively for the current year, with a 2.1% improvement in the Zacks Consensus Estimate for earnings over the last 30 days [18] Coeur Mining Inc. (CDE) - Coeur Mining operates as a primary silver and gold producer with mines in the Americas, including properties in Mexico, Bolivia, Nevada, and Alaska [19] - The company has an expected revenue and earnings growth rate of 88.3% and over 100% respectively for the current year, with a 3.8% improvement in the Zacks Consensus Estimate for earnings over the last 30 days [20]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Exact Sciences (EXAS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Exact Sciences is one of 960 companies in the Medical group. The Medical group currently sits a ...

Exact Sciences (EXAS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, EXAS crossed above the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.S ...

Core Insights - Exact Sciences Corporation (NASDAQ: EXAS) stock has experienced single-digit losses since January 1, 2025, although it has seen double-digit gains in the past month, which mitigated the overall decline [1] Company Performance - The stock remains in the negative territory year-to-date, but recent performance indicates a recovery trend with notable gains in the last month [1] Analyst Background - Gamu Dave Innocent Pasi, a financial professional with extensive experience in investment research and analysis, emphasizes the importance of financial inclusion and sustainability in investment strategies [1]

Group 1 - Exact Sciences Corporation (NASDAQ: EXAS) stock has experienced single-digit losses since January 1, 2025, although it has seen double-digit gains in the past month, which has mitigated the overall decline [1] - The company is currently focused on building a new international investment portfolio, indicating a strategic shift towards global opportunities [1] Group 2 - The article highlights the author's extensive background in financial analysis and investment research, emphasizing a strong track record in providing actionable trading ideas and well-researched investment recommendations [1] - The author is an advocate for Responsible Investment and actively promotes Environmental, Social, and Governance (ESG) principles in investment decision-making [1]